Glenview Trust co decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 7.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 8,663 shares of the medical research company’s stock after selling 717 shares during the period. Glenview Trust co’s holdings in Amgen were worth $2,258,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of AMGN. Centricity Wealth Management LLC acquired a new stake in shares of Amgen during the fourth quarter worth $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the 3rd quarter worth about $29,000. Synergy Investment Management LLC purchased a new stake in Amgen in the 4th quarter valued at about $34,000. Atala Financial Inc acquired a new position in shares of Amgen during the 4th quarter valued at about $34,000. Finally, Heck Capital Advisors LLC purchased a new position in shares of Amgen during the 4th quarter worth about $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.
Insider Transactions at Amgen
In other news, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on AMGN
Amgen Stock Performance
Shares of AMGN opened at $313.71 on Monday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm has a market cap of $168.53 billion, a price-to-earnings ratio of 41.55, a PEG ratio of 2.63 and a beta of 0.53. The business’s 50 day moving average is $291.82 and its two-hundred day moving average is $299.12.
Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.
Amgen Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date is Friday, May 16th. Amgen’s dividend payout ratio is presently 126.09%.
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
- Five stocks we like better than Amgen
- What Are Dividend Champions? How to Invest in the Champions
- How to Build the Ultimate Everything ETF Portfolio
- What Is WallStreetBets and What Stocks Are They Targeting?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Profit From Value Investing
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.